Catalyst
Slingshot members are tracking this event:
Infinity Announces Presentations On Investigational Development Candidates, Duvelisib And IPI-549, At Upcoming EHA And ASCO Meetings
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| INFI | Community voting in process | |||||
Additional Information
-- Preliminary Data from CONTEMPO, a Phase 1b/2 Combination Study Evaluating Duvelisib in Treatment-Naïve Patients with Follicular Lymphoma, to Be Presented at EHA --
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 20, 2016
Occurred Source:
http://www.ehaweb.org/congress-and-events/21st-congress/key-information-3/
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Asco Meetings, Eha, Duvelisib, Phosphoinositide-3-kinase (pi3k)-delta
